Absci (ABSI) vs Biohaven (BHVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Absci (ABSI) has outperformed Biohaven (BHVN) over the past year, gaining 113.9% versus a loss of 22.2%. Biohaven is the larger company by market cap ($1.80 billion vs $1.58 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | BHVN |
|---|---|---|
| Share price | $9.19 | $11.94 |
| Market cap | $1.58B | $1.80B |
| 1-day change | +2.74% | +0.08% |
| YTD return | +156.16% | +5.67% |
| 1-year return | +113.88% | -22.23% |
| 5-year return | -15.90% | — |
| EPS (TTM) | $-0.79 | $-4.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | — |
| Revenue growth (YoY) | -38.24% | — |
| Net income (latest FY) | $-115.18M | $-738.82M |
| Operating margin | -4297.04% | — |
| Net margin | -4113.68% | — |
| 52-week high | $12.06 | $18.57 |
| 52-week low | $2.24 | $7.48 |
| Distance from 52-week high | -23.81% | -35.69% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +56.78% | +78.14% |
| Average volume | 3.45M | 2.62M |
| Shares outstanding | 171.61M | 151.04M |
| Employees | 140 | 274 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed BHVN by 136.1 percentage points over the past year.
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
ABSI vs BHVN FAQ
Which is bigger, Absci or Biohaven?
Biohaven (BHVN) is larger, with a market capitalization of $1.80B compared with $1.58B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or BHVN?
ABSI returned +113.88% over the past 12 months, compared with -22.23% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Absci and Biohaven in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for Absci and Biotechnology: Pharmaceutical Preparations for Biohaven.